Tragen
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tragen
Immunogenex Inc.
Immunogenex's patent applications describe accessory molecules of the TNF family. The young company is working on an {ex vivo} gene therapy that induces disease-causing cells to express modified TNF ligands so that the offending cells will be recognized and killed by cytotoxic T-cells.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice